23andMe prospects notified of chapter and potential claims — deadline to file is July 14

23andMe, the genetic testing large as soon as valued within the billions, is now navigating Chapter 11 chapter and notifying hundreds of thousands of present and former prospects that they could be eligible to file claims as a part of the restructuring course of. The corporate and 11 of its subsidiaries, together with Lemonaid Well being and LPRXOne, filed for chapter safety on March 23 of this 12 months within the Japanese District of Missouri. Prospects had been alerted Sunday that they’ve till July 14 to file claims for losses incurred.

The chapter follows a tumultuous 18 months for 23andMe, marked by declining gross sales, government departures, and a devastating knowledge breach that compromised delicate private info of almost 7 million customers. The breach, publicly disclosed in October 2023, uncovered prospects’ names, beginning years, relationship labels, percentages of DNA shared with family, ancestry stories, and self-reported areas, based on TechCrunch. The fallout triggered a number of class motion lawsuits and a wave of buyer distrust that severely undercut the corporate’s consumer-facing enterprise.

Now, prospects who had been affected by that breach — particularly these notified by 23andMe that their info was compromised between Could and October 2023 — might file what is called a Cyber Safety Incident Declare. Those that suffered monetary or different damages as a result of breach can submit a declare as a part of the chapter case. Prospects with different sorts of grievances unrelated to the cyberattack, similar to points with DNA take a look at outcomes or the corporate’s telehealth companies, might submit a separate declare beneath the Common Bar Date Package deal.

Congress has additionally expressed issues concerning the privateness implications of the chapter.

23andMe’s fall from grace was swift, and its woes had been compounded by its bold however pricey enlargement into digital well being and telemedicine, which included the $400 million acquisition of Lemonaid Well being in 2021. Initially geared toward diversifying 23andMe’s choices past client DNA testing, the strikes strained 23andMe’s monetary sources and did not ship the expansion the corporate wanted.

A proposed $30 million settlement in a associated class motion lawsuit over the cyberattack stays on maintain as a result of chapter proceedings. (23andMe’s attorneys say the settlement is in dispute now that the corporate is in chapter.) Prospects who wish to protect their proper to compensation should submit a proper proof of declare no matter their participation within the class motion.

TechCrunch has reached out to 23andMe for remark.